Why We Say Cure

The pharmaceutical industry's incentive structure optimizes for chronic management. A cured person stops buying the drug. A managed person buys it for life. This is not a conspiracy theory. It is the financial logic of every investor presentation and every revenue model for every chronic disease therapy in existence. The revenue from a cure is a one-time payment. The revenue from lifelong management is annuity income.

The rare disease community uses the word "cure" deliberately. It is a refusal to accept the economic logic that makes permanent treatment more profitable than resolution.

What Cure Means Mechanistically

Gene therapy for spinal muscular atrophy (Zolgensma) is a cure. A single intravenous infusion delivers a working copy of the SMN1 gene. The cells produce the protein the child's body could not make. The disease does not progress. The child reaches motor milestones that are impossible without the gene. One dose. One time.

Gene editing for sickle cell disease (Casgevy) is a cure. CRISPR modifies the genetic error in the person's own stem cells. The corrected cells are returned to the body. They produce normal hemoglobin. The sickling stops. The pain crises stop. The genetic instruction is repaired at its source.

Enzyme replacement therapy for Pompe disease is not a cure. It provides the missing enzyme through regular intravenous infusions. The infusions must continue for life. If they stop, the disease resumes. The underlying genetic error remains. The treatment manages the consequences without addressing the cause.

The distinction matters because it defines the endpoint. A cure trial asks whether the disease comes back. A management trial asks whether the symptoms stay controlled. These are different questions with different data requirements and different durations of follow-up.

Why the Word Matters

"Cure" is a design specification. It directs research toward therapies that address root causes. Gene therapy, gene editing, and individualized antisense oligonucleotides are mechanistically curative approaches. They correct or compensate for the genetic error itself. The body then functions as it would if the error had never existed.

Using the word "cure" is not naive. It is precise. The technologies that correct genetic errors exist today. Zolgensma is approved. Casgevy is approved. Milasen was designed, manufactured, and administered to one person in under a year. The barrier to curing more rare diseases is not the absence of curative technology. It is the absence of the data infrastructure needed to develop, test, and prove curative therapies at scale.

The rare disease community's insistence on "cure" is also a statement about who the healthcare system serves. A system optimized for chronic management serves the people who sell the management. A system that pursues cures serves the people who live with the disease. The word "cure" aligns incentives with the people the system is supposed to help.

The Data Requirement

Measuring cure requires the longest follow-up of any clinical endpoint. If a child receives gene therapy for PKU at age two and the phenylalanine hydroxylase gene functions correctly afterward, confirming the cure requires decades of observation. Does the gene continue to express? Does the enzyme remain active? Are there late effects from the viral vector that delivered it? Is the person's health trajectory at age 30, at age 50, indistinguishable from someone who never had PKU?

No existing rare disease registry was designed to follow people through cure and beyond. Registries track disease. They do not track the absence of disease after treatment. The post-cure longitudinal dataset, which is the evidence that confirms whether a cure is durable, does not exist in any current infrastructure.

A data trust designed to follow people from diagnosis through treatment through cure and through the decades afterward is the infrastructure that makes "cure" measurable. The post-cure data is what enables the next approval, because it demonstrates long-term safety and efficacy to the regulatory agencies that must evaluate the next curative therapy for the next condition.

The Compounding Logic

Each cure generates data that accelerates the next. Zolgensma's long-term outcome data informs the safety evaluation of gene therapies for other neuromuscular conditions. Casgevy's durability data informs the regulatory assessment of CRISPR-based therapies for other hemoglobin disorders and beyond. The safety profile of AAV vectors established through rare disease gene therapies is now being applied to gene therapy programs for cardiovascular disease, neurodegeneration, and cancer.

Rare disease is not a niche market at the edge of medicine. It is the research and development engine for platform technologies that will serve billions of people. The families raising children with rare disease today are generating the safety data, the efficacy data, and the regulatory precedents that will determine how curative therapies reach the general population.

The ASO platform validated through milasen is being adapted for other neurological conditions. The CRISPR editing platform validated through Casgevy is being applied to conditions far more common than sickle cell disease. The AAV gene therapy vector validated through Zolgensma is the basis for gene therapy programs across dozens of conditions.

Every rare disease cure is a proof point for the platform that delivers it. The platforms that cure rare disease first will cure common disease next.

The Economic Argument

A cured person does not need lifelong medical food at $30,000 a year. A cured person does not need biweekly enzyme infusions at $300,000 a year. A cured person does not need the emergency room visits, the specialist appointments, the hospitalizations, the missed work, the caregiver burden, and the disability payments that chronic rare disease generates.

The upfront cost of a curative gene therapy ($2 to $3 million for current products) is large. The lifetime cost of managing a chronic rare disease is larger. The math is straightforward, and payers who evaluate therapies on a lifetime cost basis increasingly recognize it. The challenge is paying the upfront cost through insurance and reimbursement systems designed for chronic monthly payments.

The economic question is not whether cures save money. They do. The question is whether the payment infrastructure can accommodate a one-time expenditure that eliminates decades of downstream cost. That is a financing problem, not a medical one.

Who Uses the Word

Pharmaceutical companies rarely say "cure" in public. The legal liability of promising a cure and failing to deliver one is significant. Regulatory agencies avoid the word for similar reasons. Academic researchers prefer "durable remission" or "functional correction."

The people who use the word "cure" are the families. The parent of a child with PKU who manages the diet every day, counts every gram of phenylalanine, orders the formula, argues with insurance, and worries about cognitive outcomes at every developmental milestone uses the word "cure" because it describes the thing that would make all of that stop.

The word is not aspirational. It is mechanical. Fix the gene. Produce the enzyme. Stop the disease. That is what cure means. The technology to do it exists. The data to prove it works at scale does not yet exist. Building that data infrastructure is the project.